Our study also indicates that the dissection of CEBPD biology in the tumor microenvironment could suggest targets for developing anticancer reagents, such as the RI37 peptides demonstrated here, that may be used for cancer therapy in the future (Figure. This evidence concerns the gene CEBPD and neoplasm.